Kallyope Inc., a growing biotech focused on modulating the gut-brain axis to treat metabolic and neurological disorders, has raised $66 million that will help carry its first compounds toward the clinic and ongoing development of its discovery platform, CEO Nancy Thornberry told BioWorld. Read More
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal stem cell candidate, MSC-100-IV (remestemcel-L), met the primary endpoint in a phase III trial in children with refractory acute graft-vs.-host disease (aGVHD). Read More
While drug and radiation therapy (RT) combinations have the potential to unlock safer or more effective cancer treatments, the regulatory path for such combinations is still a frontier. And interest in pursuing a drug approval in combination with RT is often an afterthought for drug companies. Read More
Researchers led by the National Center for Nano-science Technology (NCNST), Chinese Academy of Sciences, have developed a DNA-based nanorobot and shown in mammals that it is a safe and effective means of delivering targeted cancer treatment in response to a molecular trigger. Read More
Hoth Therapeutics Inc., of New York, said it completed its $3 million series A financing to fund operations and advance its Biolexa platform. Read More
Capricor Therapeutics Inc., of Los Angeles, said a study published in Stem Cell Reports showed that cardiosphere-derived cells (CDCs) improved cardiac muscle function, walking abilities and survival in a mouse model of Duchenne muscular dystrophy. Read More
Vertex Pharmaceuticals Inc., of Boston, started the first phase III trial testing the combination of VX-659, tezacaftor and ivacaftor in patients with cystic fibrosis who have one F508del mutation and one minimal function mutation. Read More
